Copy reference, caption or embed code
- Probing for peptidic drugs (2–10 kDa) in doping control blood samples
![Extracted ion chromatograms (left, from targeted single ion monitoring [tSIM]) showing a sample from a diabetic patient after administration (regular treatment) of the fast‐acting synthetic insulin aspart and the long‐acting insulin detemir. Mass spectra (right) of insulin aspart (SIM, top), showing 5‐fold protonated precursor ion and of insulin detemir (ddMS2, bottom) with two diagnostic product ions including the attached myristic fatty acid](https://www.researchgate.net/profile/Sam-Thilmany/publication/362850873/figure/fig3/AS:11431281113568808@1673978667534/Extracted-ion-chromatograms-left-from-targeted-single-ion-monitoring-tSIM-showing-a_Q320.jpg)
Extracted ion chromatograms (left, from targeted single ion monitoring [tSIM]) showing a sample from a diabetic patient after administration (regular treatment) of the fast‐acting synthetic insulin aspart and the long‐acting insulin detemir. Mass spectra (right) of insulin aspart (SIM, top), showing 5‐fold protonated precursor ion and of insulin detemir (ddMS2, bottom) with two diagnostic product ions including the attached myristic fatty acid
Reference
Caption
Embed code